
    
      Multicenter, open, single sequence crossover study. Subject Enrolment: PrografÂ® administered
      twice daily is replaced by Prograf as study medication, administered twice daily.

      Six weeks Prograf-Treatment Phase to confirm compliance to regimen stability requirements
      (see Inclusion and Exclusion Criteria), and collection of data under Prograf treatment.

      Conversion from Prograf (twice daily, morning & evening dosing) total daily dose to MR4 once
      daily (only morning dosing) on a 1:1 (mg:mg) basis on Day 1.

      Twelve weeks MR4-Treatment Phase with study assessments for safety and efficacy.
    
  